Rigel Pharmaceuticals to Present Key Data at ASCO and EHA 2025 Conferences

Introduction

Rigel Pharmaceuticals, Inc., a prominent biotech firm specializing in oncology and hematologic conditions, has announced an exciting lineup of poster presentations scheduled for the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) Congress. These events are set to highlight innovative approaches and pivotal data surrounding their product portfolio, particularly focusing on the efficacy and safety of GAVRETO® (pralsetinib) and REZLIDHIA® (olutasidenib).

Event Details

The ASCO Annual Meeting will occur in Chicago, Illinois, and virtually from May 30 to June 3, 2025, while the EHA 2025 Congress will take place in Milan, Italy from June 12 to June 15, 2025. Rigel's participation underscores its commitment to communicating significant advancements in the treatment of cancer, marking crucial touchpoints for healthcare professionals in attendance.

Highlights of Presentations

1. GAVRETO® (pralsetinib)
Rigel's poster presentation focuses on the promising final data from the Phase 1/2 ARROW study, showcasing the treatment's effectiveness in patients with RET fusion-positive non-small cell lung cancer (NSCLC). According to Raul Rodriguez, Rigel's president and CEO, the study results exhibit substantial, durable responses across various patient demographics, supporting GAVRETO's position as as an effective treatment option in this challenging disease landscape.

In this study, the overall response rate (ORR) stood at a remarkable 70.3%, indicating a robust positive response among participants. Additionally, the median duration of response (DOR) was confirmed at 19.1 months, paving the way for GAVRETO as a critical player in treating RET fusion-positive NSCLC that typically presents unmet clinical needs.

2. REZLIDHIA® (olutasidenib)
The presentation on REZLIDHIA will emphasize its potential in managing mutated isocitrate dehydrogenase-1 (mIDH1) acute myeloid leukemia (AML), particularly in relapsed or refractory cases. Data analysis indicates that patients receiving REZLIDHIA following prior treatment regimens benefit from improved outcomes, showcasing the necessity of early intervention with this therapeutic agent. The findings bolster the argument for incorporating REZLIDHIA earlier in the treatment timeline for optimal effectiveness.

EHA Congress Presentations

During the EHA Congress, Rigel will highlight additional findings through several poster presentations:

- A post-hoc analysis on olutasidenib therapy in primary refractory AML demonstrates noteworthy response rates and safety profiles, offering new hope for a population with historically poor prognoses.
- The effect of mutation types and co-mutations on patient response offers critical insights for tailored therapeutic approaches.

Conclusion

Rigel Pharmaceuticals is looking forward to showcasing these compelling data at both conferences, emphasizing the company's continuous innovation in addressing some of the most pressing medical needs in oncology and hematology. These presentations will not only contribute to academic discourse but also reinforce Rigel's position at the forefront of transformative cancer treatment solutions. By sharing their findings with the global medical community, Rigel aims to forge deeper collaborations and foster shared knowledge that could ultimately benefit patients worldwide in their battle against cancer.

For more comprehensive details on Rigel's poster presentations, interested parties can access abstracts through the ASCO and EHA official websites leading up to the meetings.